EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing

Abeba Zewdu iD, Danielle Braggio, Gonzalo Lopez, Kara Batte, Safiya Khurshid, Fernanda Costas C de Faria, Hemant K Bid, David Koller, Lucia Casadei, Katherine J Ladner, David Wang, Valerie Grignol iD und 4 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0299962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Abeba Zewdu und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina, Department of Internal Medicine, Chapel Hill, North Carolina, United States of America. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Interleukin-6, Liposarcoma, Signal Transduction. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective therapies for retroperitoneal (RP) dedifferentiated liposarcoma (DDLPS) remain unavailable. Loco-regional recurrence occurs in >80% of cases; 5-year disease-specific survival is only 20%. DDLPS is especially prevalent in the retroperitoneum and abdomen; evaluation of the DDLPS microenvironment in these high-fat compartments appears pertinent. Adipose is a main supplier of interleukin-6 (IL6); excessive activation of IL6 signal transducer glycoprotein 130 (GP130) underlies the development of some diseases. The role of GP130 pathway activation remains unstudied in DDLPS, so we examined the role of microenvironment fat cell activation of the IL6/GP130 signaling cascade in DDLPS. All DDLPS tumors and cell lines studied expressed elevated levels of the GP130-encoding gene IL6ST and GP130 protein compared to normal tissue and cell line controls. IL6 increased DDLPS cell growth and migration, possibly through increased signal transducer and activator of transcription 1 (STAT1) and 3 (STAT3) activation, and upregulated mouse double minute 2 (MDM2). GP130 loss conveyed opposite effects; pharmacological blockade of GP130 by SC144 produced the MDM2 splice variant MDM2-ALT1, known to inhibit full length MDM2 (MDM2-FL). Although genomic MDM2 amplification is pathognomonic for DDLPS, mechanisms driving MDM2 expression, regulation, and function beyond the MDM2:p53 negative feedback loop are poorly understood. Our findings suggest a novel preadipocyte DDLPS-promoting role due to IL6 release, via upregulation of DDLPS MDM2 expression. Pharmacological GP130 blockade reduced the IL6-induced increase in DDLPS MDM2 mRNA and protein levels, possibly through enhanced expression of MDM2-ALT1, a possibly targetable pathway with potential as future DDLPS patient therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2Interleukin-6LiposarcomaSignal TransductionAlternative SplicingInterleukin-6 InhibitorsCytokine Receptor gp130AnimalsMiceHumansCell Line, TumorCell ProliferationSTAT3 Transcription FactorCell MovementGene Expression Regulation, NeoplasticSTAT1 Transcription FactorRetroperitoneal Neoplasms

Substanzen

Proto-Oncogene Proteins c-mdm2Interleukin-6Cytokine Receptor gp130STAT3 Transcription FactorSTAT1 Transcription FactorInterleukin-6 InhibitorsMDM2 protein, human

Autor:innen und Institutionen

  • University of North Carolina, Department of Internal Medicine, Chapel Hill, North Carolina, United States of America.
  • EMD Serono. 1 Technology Place, Rockland, Massachusetts, United States of America.
  • Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States of America.
  • The James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States of America.
  • Office of Academic Affairs, The Ohio State University, Columbus, Ohio, United States of America.
  • Nationwide Children's Hospital, Columbus, Ohio, United States of America.

ORCID-Profile: Abeba Zewdu, Valerie Grignol, Raphael E Pollock

Förderung

  • NCI NIH HHS
  • National Cancer Institute of the National Institutes of Health
  • U.S. Department of Defense
  • National Institutes of Health

Zitieren

APA

Zewdu, A., Braggio, D., Lopez, G., Batte, K., Khurshid, S., Costas C de Faria, F., Bid, H. K., Koller, D., Casadei, L., Ladner, K. J., Wang, D., Grignol, V., Iwenofu, O. H., Chandler, D., Guttridge, D. C., & Pollock, R. E. (2025). Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing. PLOS One. https://doi.org/10.1371/journal.pone.0299962

Vancouver

Zewdu A, Braggio D, Lopez G, Batte K, Khurshid S, Costas C de Faria F, et al. Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing. PLOS One. 2025. doi:10.1371/journal.pone.0299962

BibTeX
@article{Zewdu2025,
  author = {Zewdu, Abeba and Braggio, Danielle and Lopez, Gonzalo and Batte, Kara and Khurshid, Safiya and Costas C de Faria, Fernanda and Bid, Hemant K and Koller, David and Casadei, Lucia and Ladner, Katherine J and Wang, David and Grignol, Valerie and Iwenofu, O Hans and Chandler, Dawn and Guttridge, Denis C and Pollock, Raphael E},
  title = {Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0299962}
}
Kostenlos starten →